Early results of the clinical trial of a Chinese vaccine candidate, CoronaVac, based on the inactivated whole SARS-CoV-2 virus shows that the formulation appears to be safe and induces an antibody response in health volunteers aged 18 to 59 years. The results, published in The Lancet Infectious Diseases Journal, add to the number of vaccine […]
